Serina Therapeutics Announces Director Departure and Officer Appointments
Ticker: SER · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1708599
| Field | Detail |
|---|---|
| Company | Serina Therapeutics, Inc. (SER) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $4.9 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, officer-appointment, director-election
TL;DR
Serina Therapeutics swaps a director, names new CMO/CSO.
AI Summary
Serina Therapeutics, Inc. announced on February 11, 2025, the departure of Director Dr. David E. Bearss and the election of Dr. Robert E. T. Smith as a new director. The company also appointed Dr. Smith as Chief Medical Officer and Dr. David L. Bearss as Chief Scientific Officer. These changes are effective immediately.
Why It Matters
Changes in key leadership roles can signal shifts in strategic direction or operational focus for the company.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Serina Therapeutics, Inc. (company) — Registrant
- Dr. David E. Bearss (person) — Departing Director
- Dr. Robert E. T. Smith (person) — Elected Director and Chief Medical Officer
- Dr. David L. Bearss (person) — Chief Scientific Officer
- February 11, 2025 (date) — Effective date of changes
FAQ
Who has departed from Serina Therapeutics' board of directors?
Dr. David E. Bearss has departed from the board of directors.
Who has been appointed as the new Chief Medical Officer?
Dr. Robert E. T. Smith has been appointed as the new Chief Medical Officer.
What is the effective date of these leadership changes?
The changes are effective as of February 11, 2025.
Who was appointed as Chief Scientific Officer?
Dr. David L. Bearss was appointed as Chief Scientific Officer.
What is the company's principal executive office address?
The principal executive offices are located at 601 Genome Way, Suite 2001, Huntsville, Alabama 35806.
Filing Stats: 1,014 words · 4 min read · ~3 pages · Grade level 10.7 · Accepted 2025-02-12 16:04:58
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share SE R NYSE American Indicate
- $4.9 billion — acquired by Vertex Pharmaceuticals for $4.9 billion in May 2024. Before Alpine, he founded
Filing Documents
- ser-20250211.htm (8-K) — 30KB
- a991-pressreleasexappointm.htm (EX-99.1) — 9KB
- 0001708599-25-000016.txt ( ) — 250KB
- ser-20250211.xsd (EX-101.SCH) — 2KB
- ser-20250211_lab.xml (EX-101.LAB) — 53KB
- ser-20250211_pre.xml (EX-101.PRE) — 31KB
- ser-20250211_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure Attached hereto as Exhibit 99.1 is a press release dated February 12, 2025, for Serina Therapeutics, Inc. (the "Company"). The information in this Item 7.01 is being furnished, not filed, pursuant to Regulation FD. Accordingly, the information in this report will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that, the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release announcing the appointment of Dr. Jay Venkatesan to the Company's Board of Directors 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SERINA THERAPEUTICS, INC. Date: February 12, 2025 By: /s/ Steve Ledger Chief Executive Officer